Table 2.
Molecular Studies of Tumor Specimens
| Dasatinib 70 mg twice daily (n=9) | Dasatinib 100 mg daily + Erlotinib (n=12) | |
|---|---|---|
|
| ||
|
Primary EGFR Mutations
| ||
| Exon 19 deletion | 4 | 10 |
|
| ||
| L858R | 4 | 2 |
|
| ||
| Unable to be tested* | 1 | 0 |
|
| ||
|
Molecular abnormalities found at the time of developing acquired resistance
| ||
| T790M + Exon 19 del | 2 | 8 |
| T790M + L858R | 2 | 0 |
| T790M not found + Exon 19 del | 2 | 2 |
| T790M not found + L858R | 1 | 2 |
| T790M unable to be tested* | 2 | 0 |
|
| ||
| MET amplification present | 0 | 0 |
| MET amplification absent | 4 | 7 |
| MET amplification unable to be tested* | 5 | 5 |
*
due to insufficient tumor tissue